![expert reaction to preprint from Oxford looking at immunogenicity and efficacy of the Oxford/AstraZeneca vaccine with a 3-month gap between doses, and looking at whether data says anything about transmission | Science expert reaction to preprint from Oxford looking at immunogenicity and efficacy of the Oxford/AstraZeneca vaccine with a 3-month gap between doses, and looking at whether data says anything about transmission | Science](http://www.sciencemediacentre.org/wp-content/uploads/2021/02/Sheila-Bird-03-02-2021.png)
expert reaction to preprint from Oxford looking at immunogenicity and efficacy of the Oxford/AstraZeneca vaccine with a 3-month gap between doses, and looking at whether data says anything about transmission | Science
![Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant | UCL News - UCL – University College London Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant | UCL News - UCL – University College London](https://www.ucl.ac.uk/news/sites/news/files/pfizer-biontech_vaccine_pic2.jpg)
Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant | UCL News - UCL – University College London
![Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | The BMJ Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | The BMJ](https://www.bmj.com/content/bmj/373/bmj.n1088/F2.large.jpg)
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | The BMJ
![COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7011e2_COVID19VaccineDose2_IMAGE_12Mar21_v4_1200x627.jpg?_=39294)
COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR
![Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study - The Lancet Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study - The Lancet](https://www.thelancet.com/cms/asset/4a4effe5-53f5-4f96-9256-36262c6efc01/gr1.jpg)
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study - The Lancet
![Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study - The Lancet Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study - The Lancet](https://www.thelancet.com/cms/asset/010fc55e-684e-416e-9c4e-839b914722d9/gr1.jpg)
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study - The Lancet
![COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/figures/mm7011e2-F.gif?_=83873)